First Verisante Aura Beta Units Enter Clinics

Mr. Braun, the President and CEO of Verisante Technology (VRS – $0.54) spoke at the Canadian Association of Medical Radiation Technologists’ (CAMRT) Annual General Conference a few days ago. The conference was a success as about 1,500 technologists attended. Mr. Braun presented during the Canadian Innovation Showcase, a session that highlights Canadian companies who are breaking new ground with revolutionary approaches to diagnostic imaging and therapeutic treatment.

This conference took place at an ideal moment as Verisante placed its first beta units of the Aura in the BC Cancer Agency Research Centre and the Skin Care Centre at Vancouver General Hospital for field testing.

Frontline Health Care Workers On Board

Attending conferences, like the CAMRT’s, is important for Verisante to get frontline health care workers, like nurses and imaging technologists, informed about, and familiar with, the Verisante Aura, which received approval in Canada, the 27 EU member states and Australia as a skin cancer detection device.

The Canadian Association of Medical Radiation Technologists (CAMRT) is Canada’s national professional association and certifying body for medical radiation technologists and therapists. Approximately 12,000, CAMRT members work in over 1000 medical imaging locations in hospitals and private imaging clinics across Canada.

Although in most instances these medical professionals won’t make the purchasing decision, they will operate the device on a daily basis. As such, they need to be on board to help make the Aura the preferred skin cancer detection tool in every medical centre.

Frontline health care workers are key to reduce the long wait times and bottlenecks in medical imaging centers. The adoption of faster and more accurate technologies, like the Aura, can save the health care system time and money while helping patients with improved outcomes and reduced wait times.

Beta Units In The Field

Although the first Aura beta units have been placed in clinics, several other ones are still undergoing final safety and lab tests before they’ll go to other dermatological and skin care centers. According to management, the safety testing is very extensive before they can go to a clinic.

The Company’s plan is to field test them in clinics for about three months. During that quarter, doctors will first scan patients’ skin lesions with the Aura. When they find a suspicious lesion, it will be biopsied and analyzed. Subsequently, the Aura’s diagnoses is compared with the clinical diagnosis and the pathologist’s report.

Verisante has deliberately opted for a fairly long in-field test period, because they want to detect a minimum number of each type of skin cancer, so they’re 100% sure the device does the job.

Conclusion

Everything remains on track for Verisante to start full commercial production of the Aura later this year.

Meanwhile, the Company’s management is making people aware of the device and its capabilities. Mr. Braun is attending conferences across the globe to talk with stakeholders, so that when the time comes, first commercial devices can be sold as fast as possible.

For important disclosures, please read our disclaimer.